OASIS | Jotup

BlueWind Medical Revi™ Patient-Centric Solution for Urge Urinary Incontinence Now Available at Mount Carmel Health in Ohio

Retrieved on:

Tuesday, April 9, 2024

Physician, Patient, Tibial, OASIS, Ankle, Quality of life, Pharmacotherapy, Urinary incontinence, Safety, Commercial software, Neuromodulation, FDA, Medical device

PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).

Key Points:

PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).
"Many of my patients are looking for an alternative to ongoing drug therapy" shared Dr. Jeffrey Carey.
"Revi provides individually tailored therapy that patients deliver themselves, on their schedule, and at their convenience.
Coupled with the excellent safety and efficacy of Revi, it's a welcome choice for urge incontinence patients."

OASIS Medical Inc. Brings a New Shape to Punctal Occlusion

Retrieved on:

Saturday, April 6, 2024

Plug-in (computing), Oasis, ASCRS, OASIS, Catalog, Dry eye syndrome, Birth control

GLENDORA, Calif., April 6, 2024 /PRNewswire/ -- OASIS® Medical Inc., manufacturer and distributor of disposable surgical solutions and dry eye solution brands Oasis TEARS® and SOFT PLUG® punctal plugs launch the SOFT PLUG® Extended Duration 180-T Tapered Plug at ASCRS booth 2675 in Boston.

Key Points:

SOFT PLUG® Extended Duration 180-T Tapered Plugs are designed with a .25mm tapered end for ease of insertion into the punctal opening.
The plug then gradually widens to a .6mm diameter at the top end to contribute to occlusion of the canaliculus.
SOFT PLUG® Extended Duration 180-T Tapered Plugs are intended to temporarily block tear drainage by the occlusion of the canaliculus to temporarily treat dry eye syndrome and the dry eye components of various ocular surface diseases.
The addition of SOFT PLUG® Extended Duration 180-T Tapered Plug to OASIS line of dry eye solutions brings a robust selection of punctal occlusion to eye care providers in the US.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on:

Tuesday, March 12, 2024

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points:

License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant

Retrieved on:

Tuesday, March 19, 2024

Health, Fitness & Nutrition, Clinical Trials, Research, Pharmaceutical, Science, International Menopause Society, VMS, Menopause, OASIS, Executive Committee, Imperial College London, Woman, Hot, Safety, Elinzanetant, Phase, Marketing, Pharmaceutical industry

Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.

Key Points:

Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.
The long-term safety profile observed over 52 weeks in the OASIS 3 study is overall consistent with previously conducted studies and published data1,2 on elinzanetant.
“OASIS 3 was designed to address the important question of the long-term profile of elinzanetant.
“These results, coupled with the recent announcement of topline data for OASIS 1 and OASIS 2, strengthen our confidence in the proposed efficacy and safety of elinzanetant as a potential novel non-hormonal solution for women experiencing menopause-related symptoms.”
OASIS 3 (NCT05030584) is the third Phase III study in the OASIS clinical development program with positive topline results.

Patients in Utah Now Have Access to the Novel Revi™ Implantable Tibial Neuromodulation Device for the Treatment of Urge Urinary Incontinence

Retrieved on:

Wednesday, March 27, 2024

Physician, Patient, OASIS, University, Ankle, Quality of life, Pharmacotherapy, Urinary incontinence, Commercial software, Neuromodulation, FDA

PARK CITY, Utah, March 27, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient-centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Utah with urologist Dr. Sara Lenherr at the University of Utah.

Key Points:

"Revi is a solution for the millions of people dealing with Urge Urinary Incontinence (UUI).
I look forward to offering Revi to my patients, especially those who are unable to tolerate, afford, or are not good candidates for drug therapy," shared Dr. Sara Lenherr.
"Revi offers a patient-centered design, which allows for individually tailored therapy that patients can deliver themselves, on their schedule and at their convenience."
UUI is a common and debilitating condition, affecting approximately 16 million people in the U.S., most of whom never receive effective treatment.

Unanet GovCon Expert to Speak with GSA's Assistant Commissioner at Upcoming GovConWire Fireside Chat

Retrieved on:

Friday, March 15, 2024

CRM, Fireside, ERP, OASIS, IDIQ, GSA, Professional services, Assistant commissioner of police

Hixson, who oversees the contracts in these categories, will lead a discussion about how the GSA will support businesses in 2024, including small and disadvantaged businesses.

Key Points:

Hixson, who oversees the contracts in these categories, will lead a discussion about how the GSA will support businesses in 2024, including small and disadvantaged businesses.
Additionally, Koster and Hixson will probe the opportunities for GovCon businesses amid the recent OASIS and OASIS+ IDIQ contracts.
Kim Koster, Vice President of GovCon Product Marketing, Unanet
Tiffany Hixson, Assistant Commissioner, Professional Services & Human Capital, U.S. General Service Administration
The Fireside Chat will be virtual and is organized by Executive Mosaic LLC.
Interested participants can register for the free event through GovConWire at https://events.govconwire.com/event/gcw-fireside-chat-with-tiffany-hixso...

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

Retrieved on:

Monday, March 11, 2024

Therapy, Amgen, Safety, CD19, Breast, ASX, Ovary, Patient, OASIS, IMU, Blinatumomab, Melanoma, Vaccine

Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.

Key Points:

Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.
The trial is titled: “A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors.” See https://clinicaltrials.gov/study/NCT06063317
The combination arm of the study will see onCARlytics combined with CD19 targeting bispecific monoclonal antibody blinatumomab (marketed as Blincyto® by Amgen which currently is specifically approved only for liquid blood cancers).
onCARlytics has the potential to target and eradicate solid tumours that otherwise cannot be treated with Blincyto® therapy alone and will represent a paradigm shift in solid tumour treatment.
OASIS is a dose escalation trial that will be conducted across multiple sites across the United States, with 52 patients proposed to take part in the trial.

Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Retrieved on:

Thursday, March 7, 2024

Incidence, TNX-102, Tonix Pharmaceuticals, ASR, University, Safety, Index, ASD, Trauma, SL2, OASIS, Efficacy, IND, Parmenter, Research, Pharmaceutical industry

CHATHAM, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the publication of a research paper in the Journal Psychiatry Research. The article titled, “A Phase 3, Randomized, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder,” by Parmenter, et al. found that bedtime TNX-102 SL* treatment is well-tolerated and showed nominal improvement in PTSD severity and sleep quality measures in the first four weeks in military-related posttraumatic stress disorder (PTSD).1 The Company believes these findings suggest a potential role for short-term bedtime TNX-102 SL treatment in the immediate aftermath of traumatic events.

Key Points:

The IND supporting the OASIS trial was recently cleared,3 and the trial is expected to begin enrolling in the second quarter.
In the OASIS study, 14 days of bedtime TNX-102 SL 5.6 mg will be tested in the immediate aftermath of motor vehicle collision.
“We believe the results in the published paper suggest that bedtime TNX-102 SL has short-term activity on improving PTSD symptom severity and sleep quality in military-related PTSD.
The upcoming OASIS trial will test a 14-day short-course of bedtime TNX-102 SL therapy beginning within 24 hours of index trauma for effects on ASR symptoms and incidence of PTSD development.

Register Now for this Year's United States Electric Power Industry Seminar: Focus on Renewable Energy, ISO Markets, and Power Transactions (South Carolina, United States - March 12-13, 2024)

Retrieved on:

Monday, February 12, 2024

DUBLIN, Feb. 12, 2024 /PRNewswire/ --The "Today's U.S. Electric Power Industry, Renewable Energy, ISO Markets, and Power Transactions" training has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Feb. 12, 2024 /PRNewswire/ --The "Today's U.S. Electric Power Industry, Renewable Energy, ISO Markets, and Power Transactions" training has been added to ResearchAndMarkets.com's offering.
If you want to better understand the U.S. electric power industry and the different ways power is bought and sold, this in-depth seminar is for you.
Federal vs state regulatory conflicts, and why restructuring today's power industry and the building new power lines is such a complicated task.
John Adamiak is President and Founder of PGS Energy Training and an expert in energy derivatives and electric power markets.

WellSky® Partners With Google Cloud to Accelerate Data-Driven Innovation, Integrate Cutting-Edge AI Technology Into Solutions

Retrieved on:

Thursday, February 1, 2024

WellSky , a leading health and community care technology company, today announced a new strategic partnership with Google Cloud to leverage its secure cloud technologies, advanced data analytics tools, machine learning capabilities, and its enterprise-ready artificial intelligence (AI) platform, Vertex AI.

Key Points:

WellSky , a leading health and community care technology company, today announced a new strategic partnership with Google Cloud to leverage its secure cloud technologies, advanced data analytics tools, machine learning capabilities, and its enterprise-ready artificial intelligence (AI) platform, Vertex AI.
Over the past few years, WellSky has significantly invested in modernizing its IT infrastructure, and this partnership with Google Cloud will accelerate those efforts.
The goal is to better anticipate client needs, enabling better care for patients.
“Innovative solutions that make use of AI will dramatically improve healthcare over the next decade,” said Ryan Terry, managing director, healthcare and life sciences, at Google Cloud.
“AI technology can serve as a fundamental tool in making healthcare insights more accessible and meaningful for clinicians.